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Increased fibroblast growth factor 23 (FGF23), a bone-derived hormone involved in the
regulation of phosphate and vitamin D metabolism, has been related to the development of
cardiovascular disease (CVD) in chronic kidney disease patients and in the general popula-
tion. However, what determines higher FGF23 levels is still unclear. Also, little is known
about the influence of diet on FGF23. The aim of this study was therefore to identify demo-
graphic, clinical and dietary correlates of high FGF23 concentrations in the general
population.
Methods
We performed a cross-sectional analysis within a randomly selected subcohort of the Euro-
pean Prospective Investigation into Cancer and Nutrition (EPIC)-Germany comprising 2134
middle-aged men and women. The Human FGF23 (C-Terminal) ELISA kit was used to
measure FGF23 in citrate plasma. Dietary data were obtained at baseline via validated food
frequency questionnaires including up to 148 food items.
Results
Multivariable adjusted logistic regression showed that men had a 66% lower and smokers a
64% higher probability of having higher FGF23 ( 90 RU/mL) levels compared, respectively,
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with women and nonsmokers. Each doubling in parathyroid hormone, creatinine, and C-reac-
tive protein was related to higher FGF23. Among the dietary factors, each doubling in calcium
and total energy intake was related, respectively, to a 1.75 and to a 4.41 fold increased proba-
bility of having higher FGF23. Finally, each doubling in the intake of iron was related to an
82% lower probability of having higher FGF23 levels. Results did not substantially change
after exclusion of participants with lower kidney function.
Conclusions
In middle-aged men and women traditional and non-traditional CVD risk factors were
related to higher FGF23 concentrations. These findings may contribute to the understand-
ing of the potential mechanisms linking increased FGF23 to increased CVD risk.
Introduction
Fibroblast growth factor 23 (FGF23) is a phosphatonin involved in the regulation of phosphate,
calcium, parathyroid hormone and vitamin D metabolism [1]. Higher FGF23 levels have been
related to the development of cardiovascular disease (CVD) in chronic kidney disease patients
[2]. Furthermore, in patients undergoing coronary angiography circulating FGF23 concentra-
tions have been related to the severity and extent of coronary artery stenosis in the coronary
angiographic patients [3]. However, FGF23 recently emerged as a non-traditional CVD risk
factor also in the general population with normal renal function [4]. In both human [5] and
experimental studies [6] higher FGF23 levels have been related to left ventricular hypertrophy
(LVH). Since LVH is an independent risk factor, among others, for coronary heart disease
(CHD), heart failure and stroke [7] epidemiologic studies have investigated possible relation-
ships between FGF23 and major CVD endpoints in the general population. In particular, sig-
nificant associations between higher FGF23 concentrations and increased risk of heart failure
[8–13], total [8, 9, 14, 15] and hemorrhagic stroke [16, 17] myocardial infarction [17], CHD
[11], all cause [9] and cardiovascular mortality [11, 13] emerged. These findings were recently
confirmed in a meta-analysis of prospective cohort studies showing increased FGF23 levels
related to an increased risk of all-cause mortality, CVD events, cardiovascular mortality, stroke,
heart failure [18].
So far, less is known about factors that can modulate the plasma concentration of FGF23 in
the general population.
Previous studies have shown associations between higher FGF23 levels and smoking, dysli-
pidemia, obesity [8, 19, 20], as well as higher age, dietary phosphorus intake, history of hyper-
tension, and higher levels of PTH, serum phosphate, triglycerides, uric acid, interleukine-6,
vascular cell adhesion molecule-1, and soluble tumor necrosis factor receptor 1 [21]. However,
these relationships were observed in elderly [19, 20] and male subjects [20, 21], and in patients
with stable coronary artery disease [8]. It remains unknown if these findings are generalizable
to different populations and settings. Besides, little is known about the influence of diet on
FGF23. Increased FGF23 could be the consequence of a prolonged exposure to high dietary
phosphorus levels [22]. Yet, whether a low-phosphorus diet can prevent FGF23 elevation is
unknown since available evidence are inconsistent and unlikely conclusive [23].
In the present study we aimed to identify demographic, clinical and dietary correlates of
FGF23 and of high FGF23 concentrations in the general population. For this purpose we
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performed a cross-sectional analysis of the European Prospective Investigation into Cancer
and Nutrition (EPIC)-Germany comprising middle-aged men and women.
Methods
Study population and design
EPIC-Germany comprises two cohorts at the study centres in Potsdam (27,548 participants:
16,644 women and 10,904 men; 5th and 95th age percentiles: 36–64) and Heidelberg (25,543
participants: 13,614 women and 11,929 men; 5th and 95th age percentiles: 37–63). Participants
were recruited from the local general populations between 1994 and 1998 [24, 25].
For the present analyses a cross-sectional study design was chosen. The study sample con-
sisted of a subcohort randomly selected from the original EPIC-Germany cohort [26]
(n = 2172 participants).
Ethics Statement
Study procedures have been approved by the Ethics Committee of the Medical Association of
the State of Brandenburg and by the Ethics Committee of the Heidelberg University Medical
School, respectively for Potsdam and Heidelberg. All participants gave their written informed
consents prior their inclusion in the study.
Exposure and covariate measurements
At baseline, a blood sample was drawn, processed and stored in liquid nitrogen at −196 C [25,
27]. In 2011, FGF23, PTH, and 25-hydroxyvitamin D3 [25(OH)D3] were measured in the
Institute of Agricultural and Nutritional Science, University of Halle, Germany. The Human
FGF23 (C-Terminal) enzyme-linked immunosorbent assay (ELISA) kit (Immutopics, San Cle-
mente, CA, USA) was used to measure FGF23 concentrations in citrate plasma [28]. Our
choice to measure the C-Terminal FGF23 rather than the intact FGF23 was driven by the sig-
nificant diurnal variation of the latter, considering that a stable concentration during the entire
day [29] and over time [28], as shown for the C-Terminal FGF23, is a prerequisite of a reliable
marker.
Plasma PTH (intact) was measured by an ELISA Kit (Biomerica, Irvine, CA, USA). The
plasma concentration of 25(OH)D3 was analysed by LC-MS/MS as described previously [30,
31]. The lower limit of quantification (LOQ) was 10 RU/mL, 10 pg/mL, and 4.6 ng/mL respec-
tively for FGF23, PTH, and 25(OH)D3.
In Potsdam high-density lipoprotein cholesterol (HDL), total cholesterol and C-reactive
protein (CRP) were measured with an automatic analyzer (ADVIA 1650, Siemens Medical
Solutions, Erlangen, Germany) in 2007 at the Department of Internal Medicine of the Univer-
sity of Tübingen, Germany, while plasma creatinine was measured in 2008. In Heidelberg
plasma creatinine was measured at the Stichting Huisartsen Laboratorium (Breda, The Nether-
lands). The Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) was
used to estimate glomerular filtration rate (eGFR) [32]. To account for citrate’s dilution factor
biomarkers’ concentrations were multiplied by 1.1.
Lifestyle characteristics, including sports activity and smoking history were documented at
baseline by trained interviewers during PC-guided interview [24]. Total physical activity was
assessed with the Cambridge Physical Activity Index [33]. In particular, this index combines
self-reported occupational activity, categorized as sedentary, standing, manual, or heavy man-
ual occupation, with time participating in cycling and sports. The sum of hours per week spent
on cycling and sports were categorized in four levels and participants divided into four
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mutually exclusive categories, i.e. inactive (sedentary job and no recreational activity), moder-
ately inactive, moderately active, and active (sedentary job with>1 h recreational activity per
day, standing or physical job with some recreational activity, or a heavy manual job). Education
was categorized into none, vocational school or less, technical school, secondary school, and
university. Prevalent hypertension, hyperlipidemia, and diabetes were self-reported at baseline.
Anthropometric measures. Weight and height were measured with participants not wear-
ing shoes. In Heidelberg, waist circumference was measured at the narrowest circumference of
the torso, while in Potsdam at the midpoint between the lower ribs and iliac crest. Hip circum-
ference was measured over the buttocks. To reduce heterogeneity due to protocol differences
corrected measures of each participant’s body weight, waist and hip circumference were used.
Body mass index (BMI) was defined as weight in kg divided by the square of the height in
meters (kg/m2).
Dietary information. Dietary information was obtained with a food frequency question-
naire (FFQ) in the baseline assessment of EPIC-Germany, including up to 148 food items [25].
The optical readable FFQ was designed to capture the usual food and nutrient intake of indi-
viduals during the past 12 months.
Statistical analysis
Right skewed variables were natural log-transformed. Analysis of covariance was used to com-
pare the general characteristics including selected biomarkers according to quartiles of FGF23
concentrations.
FGF23, PTH and 25(OH)D3 values below or above the limit of quantification (LOQ) were
substituted with the LOQ and a multivariable multiple imputation was used to impute missing
values for the remaining variables [34] (S1 Table for the amount of missing data). SAS PROC
MI with the Markov Chain Monte Carlo method for arbitrary missing patterns was used to
generate 20 imputed datasets. The logarithmic transformation was taken for all the continuous
right skewed variables. SAS PROCMIANALYZE was used to combine the results of the analy-
ses on 20 imputed datasets and to generate valid statistical inferences.
To identify FGF23 correlates a regression analysis based on the best subsets regression
procedure was applied, with FGF23 concentrations as dependent variable and two categories
of independent variables (dietary and non-dietary covariates). Independent variables were
selected based on a priori knowledge: age, sex, BMI, waist circumference, prevalent hyperten-
sion, hyperlipidemia, diabetes, and cardiovascular disease, educational attainment, physical
activity, smoking status, parathyroid hormone, 25(OH)D3, creatinine, total and HDL-choles-
terol, C-reactive protein (CRP), season of blood draw, intakes of total dietary fat, carbohydrate,
protein and fibre, phosphorus, calcium, potassium, magnesium, iron, alcohol, energy, and use
of calcium supplements. Both physical activity and dietary total protein intake were categorized
into quartiles to take nonlinear relationships into account. To estimate the inorganic phospho-
rus intake as a potential predictor of FGF23 we calculated the ratio of phosphorus to total pro-
tein intake as this ratio reflects the amount of inorganic phosphorus from food additives best
[35].
The best subsets regression procedure was performed on each multiply imputed dataset.
FGF23 correlates were kept in the final model, chosen based on the Mallow's Cp-statistic and
Akaike‘s Information criterion, as identified in each multiply imputed dataset. A multivariable
linear regression analysis was then used to investigate the relations between plasma FGF23 and
the identified best set of correlates. Furthermore, a logistic regression model was performed to
determine the correlates associated with higher FGF23 levels using a cut-off point of 90 RU/
mL (n = 269) [16, 17]. Results were expressed as Odds Ratio (OR) and 95% confidence interval
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(95% CI). For a better interpretation of the results, both biomarkers and dietary data were log
base 2 transformed and results interpreted as OR per 2-fold increase in predictors.
Analyses were performed with SAS 9.4 (SAS Institute, Cary, NC). Statistical tests were two-
sided and P values<0.05 considered statistically significant.
Exclusion criteria
38 participants in the lowest and highest first percent distribution of the ratio of total energy
intake to energy requirement were excluded from the analyses, leaving a final sample of 2,134
subjects.
Sensitivity analysis
Analyses were repeated after exclusion of 73 participants with eGFR<60 mL/min/1.73m2 due
to concern of renal function-related increase in FGF23 concentrations.
Results
Of the study population (n = 2,134) 44.1% were male and 55.9% were female with a median
age of 51.7 years, interquartile range [(IQR): 43.7–58.3)]. Overall, median FGF23 concentra-
tions were 53.7 RU/mL, IQR: 39.9–71.5. Tables 1 and 2 show, respectively, demographic, life-
style, clinical, and dietary characteristics of the EPIC-Germany participants by quartiles of
FGF23concentrations. Individuals with higher FGF23 levels (median in the highest FGF23
quartile: 90.3 RU/mL, interquartile range: 78.3–120.0) were more likely to be women with
higher waist circumference, to have higher BMI and to be smokers. Increasing quartiles of
FGF23 were associated with higher creatinine, PTH and CRP levels, but not 25(OH) D3
(Table 1). Regarding diet, participants in the upper FGF23 quartile had higher intakes of phos-
phorus, calcium, phosphorus to protein ratio and total energy intake (Table 2).
The best subset of FGF23correlates is shown in Table 3. In the multivariable linear regres-
sion model, based on the best subset in which each predictor was mutually adjusted for each
other, significant associations were observed between FGF23 and sex, smoking, PTH, creati-
nine, total cholesterol, CRP, intakes of calcium, iron, alcohol and total energy (Table 3).
Results from a multivariable logistic regression analysis indicate that men had a 66% lower
probability and smokers a 64% higher probability of having FGF23 levels higher than 90 RU/
mL (Table 4). Furthermore, each doubling in PTH, creatinine, and CRP was related to a higher
probability of having increased FGF23. Among the dietary factors, each doubling in dietary
calcium and total energy intake was related, respectively, to a 1.75 and to a 4.41 fold increased
probability of having higher FGF23; in contrast, each doubling in iron intake was related to an
82% lower probability.
The same subset of FGF23 predictors was identified after exclusion of participants with
eGFR<60 mL/min/1.73 m2, and results did not substantially change after multivariable linear
and logistic regression analyses (Tables 3 and 4).
When the same analyses were repeated including the ratio between phosphorus and total
protein as potential FGF23 predictor results were highly comparable to those reported in
Table 3, with the dietary phosphorus to protein ratio emerging as a new predictor of FGF23
instead of calcium intake (S2 and S3 Tables).
Discussion
In this cross-sectional analysis of middle-aged participants, sex, physical activity, smoking,
PTH, creatinine, total- and HDL-cholesterol, CRP, total protein, calcium, iron, alcohol and
FGF23 and Its Correlates
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total energy intake were identified as main potential predictors of FGF23. In particular, when
these correlates were then studied in relation to FGF23 concentrations, mutually adjusted for
each other, female sex, smokers, PTH, creatinine, and CRP, were all independently and posi-
tively associated with higher plasma FGF23 concentrations. In addition, intakes of calcium and
total energy were positively related to higher FGF23 concentrations. Interestingly, iron intake
was inversely related to higher FGF23.
Overall, our findings regarding positive associations between smoking, PTH, creatinine,
CRP and higher FGF23 concentrations are in line with other epidemiologic studies conducted
on the topic. However, these previous studies were mainly conducted in men [21, 36], elderly
[8, 19, 36], or patients with coronary artery disease [8]. As such, the current study supports and
generalizes the previous findings to a population of Caucasian middle aged men and women.
In addition, the present findings expand our knowledge of FGF23 correlates by showing male
sex and iron intake to be negatively related to higher FGF23 concentrations, and calcium and
total energy to be positively related to higher FGF23 concentrations.
In line with another study, women had higher FGF23 levels than men [37]. Since increased
FGF23 has been related to increased risk of major CVD, as also shown in our previous studies
[12] [17], interestingly this finding may contribute to increase our understanding on why the
risk of CVD in middle-aged women begins to approach the male risk [37]. Also smokers had
higher FGF23 concentrations in our study population. There is no clear explanation on how
smoking might influence FGF23 levels. However, a recent experimental study observed
increased plasma FGF23 levels in mice after injection of cadmium [38]. Since smokers have
Table 1. Demographic, lifestyle, and clinical characteristics (potential predictors) of EPIC-Germany participants, overall and according to sex spe-
cific quartiles (Q) of FGF23 levels.
Characteristics All Q1 Q2 Q3 Q4
n 2134 533 534 533 534
Age, yrs a 51.1 (50.7–51.5) 50.6 (49.9–51.3) 51.1 (50.3–51.8) 51.1 (50.3–51.8) 51.6 (50.9–52.4)
Body mass index, kg/m2 a 26.1 (25.9–26.3) 25.7 (25.3–26.0) 26.3 (26.0–26.7) 26.0 (25.7–26.4) 26.6 (26.1–26.9)
Waist circumference, cm a
Men 95.6 (95.0–96.3) 94.3 (93.0–95.6) 96.2 (94.9–97.5) 95.7 (94.4–97.0) 96.3 (95.0–97.6)
Women 80.7 (80.0–81.4) 79.4 (78.1–80.7) 80.3 (79.0–81.7) 80.8 (79.5–82.1) 82.2 (80.9–83.4)
Prevalent Comorbidities, % b
Cardiovascular disease 3.3 3.0 3.4 3.2 3.7
Hypertension 33.8 33.0 32.8 32.3 37.1
Hyperlipidemia 31.6 29.3 32.2 33.4 31.4
Diabetes 3.7 3.6 4.1 3.0 4.3
High educational level, % b 34.4 37.7 35.2 33.0 31.8
High physical activity, % b 19.9 16.1 20.4 22.7 20.2
Smokers, % b 21.0 18.8 17.0 21.2 27.0
Markers a
PTH, pg/mL 27.0 (18.1–39.0) 24.8 (26.3–26.0) 26.1 (24.9–27.4) 26.5 (25.3–27.9) 29.6 (28.2–31.1)
25(OH)D3, ng/mL 17.6 (12.5–23.5) 16.6 (16.0–17.2) 16.8 (16.2–17.5) 17.0 (16.3–17.6) 17.0 (16.3–17.7)
Creatinine, mg/dL 0.82 (0.82–0.83) 0.80 (0.78–0.82) 0.82 (0.81–0.84) 0.83 (0.81–0.84) 0.85 (0.83–0.87)
Total cholesterol, mg/dL 220.4 (218.0–222.7) 213.4 (209.0–218.2) 223.7 (219.0–228.4) 221.3 (216.7–225.9) 222.8 (218.1–227.5)
HDL, mg/dL 56.6 (55.8–57.4) 57.2 (55.7–58.7) 57.2 (55.7–58.7) 56.2 (54.7–57.7) 55.8 (54.3–57.3)
Data are expressed as:
a Mean and 95% Conﬁdence Interval (CI)
b Percentage.
doi:10.1371/journal.pone.0133580.t001
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markedly increased cadmium levels in their blood [39] this might explain the observed positive
association with higher FGF23.
To the best of our knowledge, this is the first observational study reporting relationships
between higher FGF23, and dietary intakes of calcium, iron, and total energy.
Calcium has been suggested to modulate FGF23 production [40]. The hypocalcemia
observed in Wistar rats with normal kidney function, fed with a low-calcium/low–vitamin D
diet, was associated with lower FGF23 levels. Interestingly, the same authors observed that an
increase in dietary calcium intake in parathyroidectomized rats increased serum calcium and
FGF23, decreased calcitriol levels and did not change the phosphorus levels [40]. Furthermore,
in an open-label crossover study, subjects adhering to the high phosphate/calcium diet had
increased serum FGF23 levels [41]. Overall, these findings suggest that calcium deficiency
might reduce circulating FGF23 levels.
Despite high dietary phosphorus intake has been suggested to increase FGF23 levels [42,
43], in the present study it was not identified as a significant positive predictor. Though our
findings are in line with those of the Chronic Renal Insufficiency Study [44], in which in stage
2–4 CKD patients no significant association was observed between FGF23 and dietary phos-
phorus intake, in the Health Professionals Follow-up Study each 500 mg increase in dietary
phosphorus intake was associated with 3.4 RU/mL higher serum FGF23 levels[45]. Yet,
whether a low dietary phosphorus diet can prevent FGF23 elevation is unknown since available
evidence are inconsistent and unlikely conclusive. Also, no human clinical trials confirming or
refuting this hypothesis exist [23]. Even so, whether FGF23 levels change after a dietary phos-
phate load, how this might occur is still not entirely understood [42, 46].
Table 2. Dietary characteristics (potential predictors) of EPIC-Germany participants according to sex specific quartiles (Q) of FGF23 levels.
Dietary variables Q1 Q2 Q3 Q4
n 533 534 533 534
Median (IQR)a 31.2 (25.3–35.9) 46.5 (43.3–50.3) 61.5 (57.5–66.1) 90.3 (78.3–120.0)
Macronutrients, %EIb
Carbohydrate 43.9 44.4 44.8 44.5
Total protein 15.3 15.1 15.1 14.9
Animal protein 8.1 7.8 7.9 7.7
Plant protein 4.4 4.5 4.5 4.4
Fat 35.1 35.0 35.1 35.4
Fibre 2.2 2.2 2.2 2.1
Alcohol 5.7 5.5 5.0 5.2
Minerals, mg/dayc
Phosphorus 1340 (1304–1375) 1327 (1291–1362) 1354 (1318–1389) 1396 (1361–1432)
Calcium 884.6 (854.6–914.6) 871.6 (841.7–901.5) 879.9 (850.0–909.9) 940 (910–970)
Potassium 3085(3011–3158) 3114 (3041–3188) 3132 (3059–3206) 3170.5 (3097.2–3243.9)
Magnesium 375 (366–384) 379 (370–388) 382 (372–391) 386 (377–395)
Phosphorus to protein ratio, mg/g 17.7 (17.5–17.9) 17.8 (17.6–18.0) 17.9 (17.7–18.1) 18.2 (18.0–18.5)
Intake calcium preparation, %b 3.8 4.5 5.6 5.1
Total energy intake, kcal/day 2027 (1973–2081) 2029 (1975–2083) 2056 (2002–2111) 2104 (2050–2158)
Data are expressed as:
a Median and interquartile range (IQR)
b Percentage
c Mean and 95% Conﬁdence Interval (CI).
doi:10.1371/journal.pone.0133580.t002
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Table 3. Multivariable linear regression for the associations between FGF23 concentrations and the best subset of FGF23 correlates, mutually
adjusted for each other.
Whole study population Exclusion eGFR < 60 mL/min/1.73m2
Parameter β coefﬁcient (95% CI) P valuea β coefﬁcient (95% CI) P valuea
n = 2134 n = 2061
Men -0.21 (-0.28;-0.14) <0.001 -0.22 (-0.30;-0.15) <0.001
Physical activity, Q2 -0.0004 (-0.07;0.07) 0.99 -0.003 (-0.07;0.07) 0.93
Physical activity, Q3 -0.01 (-0.08;0.07) 0.89 -0.01 (-0.08;0.07) 0.89
Physical activity, Q4 0.07 (-0.01;0.15) 0.08 0.08 (-0.01;0.16) 0.07
Smokers 0.12 (0.06;0.18) <0.001 0.12 (0.06;0.19) <0.001
PTH, pg/mLb 0.13 (0.08;0.17) <0.001 0.13 (0.08;0.16) <0.001
Creatinine, mg/dLb 0.28 (0.14;0.41) <0.001 0.27 (0.11;0.43) 0.001
Total cholesterol, mg/dL 0.001 (0.00003;0.001) 0.04 0.001 (0.0001;0.001) 0.01
HDL-cholesterol, mg/dL -0.002 (-0.003;-0.0001) 0.06 -0.002 (-0.003;-0.0001) 0.04
C-reactive protein, mg/dLb 0.03 (0.01;0.05) 0.01 0.02 (-0.001;0.04) 0.07
Total protein intake, Q2 0.04 (-0.04;0.11) 0.37 0.02 (-0.06;0.10) 0.63
Total protein intake, Q3 -0.03 (-0.11;0.06) 0.41 -0.05 (-0.13;0.03) 0.21
Total protein intake, Q4 -0.04 (-0.12;0.05) 0.42 -0.05 (-0.15;0.04) 0.23
Calcium intake, mg/dLb 0.10 (0.03;0.18) 0.01 0.04 (-0.07;0.15) 0.45
Iron intake, mg/db -0.25 (-0.42;-0.08) 0.005 -0.29 (-0.47;-0.12) 0.001
Alcohol intake, g/db -0.02 (-0.04;-0.002) 0.03 -0.02 (-0.04;-0.001) 0.07
Energy intake, kcal/db 0.25 (0.08;0.42) 0.003 0.21 (0.01;0.40) 0.03
eGFR stands for estimated glomerular ﬁltration rate; Q2, Q3, Q4 stand for quartile 2, 3 and 4.
a Based on mutual adjustment.
b Natural log transformed.
doi:10.1371/journal.pone.0133580.t003
Table 4. Odd ratios (OR) and 95%Confidence Intervals (CI) for the associations between high FGF23 (> = 90 RU/mL) and the best subset of its sig-
nificant correlates, mutually adjusted for each other.
Whole study population Exclusion eGFR < 60 mL/min/1.73m2
Predictors OR (95%CI) P valuea OR (95%CI) P valueb
FGF2390 RU/mL n = 269 n = 256
Men 0.34 (0.24–0.49) <0.001 0.28 (0.18–0.42) <0.001
Smoking 1.64 (1.21–2.25) 0.002 1.62 (1.18–2.22) 0.003
PTH, pg/mLc 1.29 (1.10–1.50) 0.001 1.27 (1.08–1.49) 0.004
Creatinine, mg/dLc 2.17 (1.34–3.51) 0.002 2.29 (1.21–4.33) 0.01
C-reactive protein, mg/Lc 1.16 (1.03–1.20) 0.005 1.10 (1.02–1.19) 0.01
Total cholesterol, mg/dL 1.00 (1.00–1.00) 0.47 1.00 (1.00–1.00) 0.82
Calcium intake, mg/dc 1.48 (1.11–1.96) 0.007 — —
Iron intake, mg/dc 0.30 (0.16–0.57) <0.001 0.30 (0.16–0.57) <0.001
Alcohol intake, g/dc 0.94 (0.88–1.01) 0.07 0.95 (0.89–1.02) 0.17
Energy intake, g/dc 2.80 (1.50–5.20) 0.001 3.71 (2.03–6.79) <0.001
a Based on mutual adjustment for the whole study population (n = 2134).
b Based on mutual adjustment after exclusion of participants with estimated glomerular ﬁltration rate (eGFR) < 60 mL/min/1.73m2 (n = 2061).
c Log base 2 transformed.
doi:10.1371/journal.pone.0133580.t004
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Besides calcium and phosphorus, an emerging area of investigation is represented by the
potential regulatory role of iron on FGF23 levels [47, 48]. In the present study, each doubling
in iron intake was related to an 82% lower probability of having higher FGF23 levels. The pres-
ent finding supports the results of a recent study showing increased FGF23 levels in elderly
subjects with low iron levels [49]. As reviewed by Bhattacharyya and colleagues [47], and later
also by Gutierrez [50], there could be a clear involvement of iron in the FGF23 expression and/
or secretion [51, 52].
To our knowledge, no studies so far have identified energy intake as a significant predictor
of FGF23 concentrations. Although the role of energy intake in modulating FGF23 concentra-
tions cannot be ruled out in this cross-sectional study, we could speculate that this finding
might involve a dysregulation of α-klotho expression, the FGF23 regulating hormone and co-
receptor [53], with a mechanism similar to that inducing klotho expression by calorie restric-
tion [54].
Overall, these findings make the link between FGF23 and diet even more biologically plausi-
ble. Yet, further studies are warranted to determine the underlying mechanism of these
relationships.
Limitations of our study include the cross-sectional design which does not enable determi-
nation of causality. FFQ may have underestimated the intake of phosphorus and protein. Hid-
den sources of phosphate added to foods in form of additives are usually not included in the
food composition tables. However, considering that phosphorus is naturally found in protein-
rich foods the ratio between phosphorus and protein has been suggested as a more appropriate
method for estimating phosphorus intake from foods [35]. Besides, this method would ensure
the computation of the protein content of a given food with the lowest possible phosphorus
amount. Furthermore, this ratio has been found to be independent of the portion consumed
and less influenced by systematic underestimation of total food consumption [55]. Interest-
ingly, in a parallel analysis using the dietary phosphorus to protein ratio as FGF23 correlates
we observed a 5.4 fold increased probability of having FGF23 levels higher than 90 RU/mL.
Yet, this observation might add further strength to the hypothesized role played by dietary
phosphorus intake on FGF23. Nevertheless, since large quantities of phosphate can originate
from membrane phospholipids and in order to better estimate dietary phosphorus intake it
would have been useful to analyse the amount of phosphate in the 24-h-urine. However, urine
phosphate, as well as blood calcium and phosphorus levels, was not available in the present
study. Another limitation is that data used for this investigation were collected about two
decades ago; therefore nutritional intakes in particular may have changed since then. However,
although absolute food intake may be different in the long run, the relation between dietary
data and FGF23 concentrations is assumed to be similar over time. Finally, because this study
was not designed to investigate biological mechanisms, further studies are necessary to under-
stand at which level the identified correlates influence FGF23 concentrations.
Conclusions
The observed associations between higher FGF23 and other traditional and non CVD risk fac-
tors may help to shed light on the possible pathophysiological mechanisms linking increased
FGF23 to increased cardiovascular risk in the general population.
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